Study Title and Description
A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Key Questions Addressed
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.|
|Author||Christodoulakos GE., Botsis DS., Lambrinoudaki IV., Papagianni VD., Panoulis CP., Creatsa MG., Alexandrou AP., Augoulea AD., Dendrinos SG., Creatsas GC.|
|Country||2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, 27 Themistokleous Street, GR-14578 Dionysos, Athens, Greece.|
Pubmed ID: 16140483
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.